Welcome!

News Feed Item

Pressure BioSciences, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update

Record Total Revenue Reported, Led by Increases in Products & Services (+21%), Consumables (+158%), and Grant (+23%) Revenue (Y/Y); Investor Conference Call Scheduled for Tuesday, November 14, 2017 at 4:30 PM EDT

SOUTH EASTON, MA -- (Marketwired) -- 11/14/17 -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments and related consumables to the worldwide life sciences industry, today announced financial results for the third quarter of 2017, provided a business update, and offered limited guidance on its expected revenue for remainder of FY 2017.

Mr. Joseph L. Damasio, Jr., VP of Finance and CFO at PBI said: "We are pleased with the strong revenue growth demonstrated in the 2017 third quarter. This growth included a record for quarterly total revenue, propelled by a 158% increase in consumable sales (also a quarterly record). Product gross profit margin remained steady at about 47%."

Mr. Damasio continued: "We believe the revenue growth reported in the third quarter and year-to-date will not only continue in Q4 2017 and beyond, but will accelerate to an even greater rate as our new sales team begins to meet with existing and potential customers throughout the U.S. To that point, Q4 2017 Purchase Orders and Purchase Indications (90% estimated probability of closing) through early November have already exceeded products & services revenue for the full 2016 fourth quarter. We remain confident that we are on the path to future expansion, profitability and success."

Q3 2017 Financial Highlights

  • Total Revenue increased 21%, from $535,334 in Q3 2016 to $646,061 (a new record for any quarter)
  • Products & Services Revenue increased 21%, from $500,949 in Q3 2016 to $603,726 (new quarterly record)
  • Consumable Sales increased 158%, from $32,811 in Q3 2016 to $84,594 (new quarterly record)
  • Grant Revenue increased 23%, from $34,385 in Q3 2016 to $42,335

Q3 2017 (plus October) Operational Highlights

  • Completed the staffing of our new 5-person field sales team and filled Director of Sales North America position
  • Established our first Center of Excellence in Asia, expected to significantly impact PBI's expansion into China
  • PBI & Phasex Corp announced a strategic collaboration in nanoemulsions technology to work towards the deliverance of unprecedented shelf-stable mixtures of normally immiscible materials that address large and diverse markets in food, nutraceuticals, pharmaceuticals, cosmetics, inks, paint, lubricants and other product areas
  • Multiple scientific presentations throughout Europe expected to accelerate PBI's penetration in Europe
  • Received first two issued patents on our widely-applicable, high pressure-based Ultra Shear Technology (UST)
  • PBI's next-generation Barocycler 2320EXTREME named a FINALIST in the prestigious 2017 R&D 100 Awards

Mr. Richard T. Schumacher, President and CEO of PBI, said: "We have a new, multi-functional, CE Marked, award-winning Barocycler instrument that we believe can significantly expand our sales potential by filling multiple needs in the biopharma industry. We have a new six-person, experienced, and highly capable sales and marketing team that can be aggressive and proactive in its selling functions, compared to the one-person, reactive sales effort that was our capability just a few months ago. In addition, we are very excited about our new, widely-applicable patented Ultra Shear Technology ("UST") platform that we believe will allow us to quickly expand into large new markets, such as nutraceuticals, cosmetics, and clean-label food."

Mr. Schumacher continued: "Our goal for Q4 2017 and beyond is to continue to accelerate our sales growth and closely control expenses as we move firmly towards profitability and financial self-sufficiency. We have spent a lot of time and money over the past few years preparing for this opportunity. We believe we are ready and taking all necessary actions to grow our momentum and fully exploit the exciting growth and new markets potential that we have long envisioned."

Financial Results: Q3 2017 vs. Q3 2016

Total revenue for the 2017 third quarter was $646,061 compared to $535,334 during the same period in 2016, an increase of $110,727 or 21%. This increase was primarily attributable to increases in both instrument and consumable sales. We believe total revenue will continue to increase on a year/year comparative basis for the remainder of 2017.

Products & Services revenue increased to $603,726 in Q3 2017 compared to $500,949 for the prior year same period, an increase of 21%. Comparing Q3 2017 to Q3 2016, instrument sales increased to $410,906 from $383,527, an increase of 7%, while consumable sales increased to a record $84,594 from $32,811, an increase of 158%. We believe products and services revenue will continue to increase on a year/year comparative basis for the remainder of 2017.

Grant revenue increased to $42,335 in the third quarter 2017 from $34,385 in the prior year period, an increase of 23%. We believe grant revenue will continue to increase in the final quarter of 2017.

Operating loss increased to $1,125,272 in Q3 2017 from $451,807 for the same period in 2016, an increase of $673,465. This increase was due primarily to a significant one-time credit of approximately $400,000 received in Q3 2016 from a former professional service provider. The remaining increase in 2017 operating loss was mostly due to headcount increases in sales and marketing and significant charges related to the registration statement process for a proposed $12.5 million financing and concomitant U.S. equities exchange up-list, which was withdrawn by the Company in August 2017.

Net loss per common share -- basic and diluted -- was $(2.07) for the quarter ended September 30, 2017 compared to net loss per share -- basic and diluted of $(0.96) for the same period in 2016. This increase in net loss per share was due to the significant increase in Q3 2017 operating loss, which as described above, was primarily related to one-time charges stemming from the August 2017 withdrawal of a registration statement, and a one-time credit of approximately $400,000 received in Q3 2016 from a former service provider.

Financial Results: First Nine Months 2017 vs. First Nine Months 2016

Total revenue for the 2017 first nine months was $1,737,790 compared to $1,556,776 for the prior year same period, an increase of $181,014 or 12%. This increase was primarily due to higher revenue from instrument and consumable sales, as described below.

Products & Services revenue increased to $1,610,124 for the first nine months of 2017 compared to $1,429,487 for the same period in 2016, an increase of 13%. Comparing the first nine months of 2017 to the same period in 2016, instrument sales increased to $1,153,883 from $1,026,888, an increase of 12%, while consumable sales increased to $200,223 from $149,819, an increase of 34%.

Grant revenue remained steady at $127,666 in the first nine months of 2017 compared to $127,289 in the prior year period.

Operating loss was $3,328,664 for the first nine months of 2017 compared to a loss of $2,558,448 for the same period in 2016, an increase of $770,216. This increase was primarily due to the hiring of four field sales directors in 2017, costs stemming from the August 2017 withdrawal of a registration statement, the hire of a full-time CFO, and other expenses related to the growth of the business. Our Q1-Q3 2017 operating loss also increased due to the effect of approximately $400,000 in credits received in the prior year period against charges incurred with a former professional service provider.

Net loss per common share -- basic and diluted -- was $(7.28) for the nine months ended September 30, 2017 compared to a net loss per common share -- basic and diluted -- of $(6.81) for the same period in 2016.

Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, November 14, 2017. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBIO Third Quarter 2017 Financial Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay ID Number: 22751. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities are emerging in the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water, fluoropolymers and alcohol, etc.), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for first nine months ended September 30, 2017 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

                 PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (UNAUDITED)

                           For the Three Months       For the Nine Months
                                   Ended                     Ended
                               September 30,             September 30,
                         ------------------------  ------------------------
                             2017         2016         2017         2016
                         -----------  -----------  -----------  -----------
Revenue:
Products, services,
 other                   $   603,726  $   500,949  $ 1,610,124  $ 1,429,487
Grant revenue                 42,335       34,385      127,666      127,289
                         -----------  -----------  -----------  -----------
  Total revenue              646,061      535,334    1,737,790    1,556,776
                         -----------  -----------  -----------  -----------

Costs and expenses:
Cost of products and
 services                    328,743      262,894      852,039      727,698
Research and development     239,326      268,317      744,565      925,015
Selling and marketing        301,676      224,380      814,796      609,501
General and
 administrative              901,588      231,550    2,655,054    1,853,010
                         -----------  -----------  -----------  -----------
  Total operating costs
   and expenses            1,771,333      987,141    5,066,454    4,115,224
                         -----------  -----------  -----------  -----------

  Operating loss          (1,125,272)    (451,807)  (3,328,664)  (2,558,448)

Other (expense) income:
Interest expense, net     (1,554,379)  (1,116,328)  (4,431,950)  (2,961,708)
Other expense                      -         (200)      (1,039)      (1,112)
Impairment loss on
 investment                        -            -       (6,069)           -
Incentive warrants for
 warrant exercises                 -            -     (186,802)           -
Gain on extinguishment
 of debt                      90,862            -       90,862            -
Change in fair value of
 derivative liabilities      245,213      623,128      (26,014)    (412,500)
                         -----------  -----------  -----------  -----------
  Total other expense     (1,218,304)    (493,400)  (4,561,012)  (3,375,320)
                         -----------  -----------  -----------  -----------

Net loss                  (2,343,576)    (945,207)  (7,889,676)  (5,933,768)
                         -----------  -----------  -----------  -----------

Net loss per share
 attributable to common
 stockholders - basic
 and diluted             $     (2.07) $     (0.96) $     (7.28) $     (6.81)

Weighted average common
 stock shares
 outstanding used in the
 basic and diluted net
 loss per share
 calculation               1,133,791      980,846    1,084,370      871,325


                 PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
                        CONSOLIDATED BALANCE SHEETS
                                (UNAUDITED)

                                               September 30,   December 31,
                                                    2017           2016
                                               -------------  -------------
                    ASSETS
CURRENT ASSETS
Cash and cash equivalents                      $      18,723  $     138,363
Accounts receivable, net of $28,169 reserve at
 September 30, 2017 and December 31, 2016            548,316        281,320
Inventories, net of $20,000 reserve at
 September 30, 2017 and December 31, 2016          1,122,782        905,284
Prepaid income taxes                                   7,482          7,405
Prepaid expenses and other current assets            146,278        258,103
                                               -------------  -------------
  Total current assets                             1,843,581      1,590,475
Investment in available-for-sale equity
 securities                                           25,986         25,865
Property and equipment, net                           19,004          9,413
                                               -------------  -------------
TOTAL ASSETS                                   $   1,888,571  $   1,625,753
                                               =============  =============

     LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable                               $     853,173  $     407,249
Accrued employee compensation                        298,675        249,596
Accrued professional fees and other                1,352,658        956,884
Deferred revenue                                     313,992        159,654
Revolving note payable, net of unamortized
 debt discounts of $335,833 and $637,030,
 respectively                                      3,164,167        612,970
Related party convertible debt, net of debt
 discount of $65,240 and $0, respectively            225,894              -
Convertible debt, net of unamortized debt
 discounts of $355,375 and $2,235,839,
 respectively                                      6,315,995      4,005,702
Other debt, net of unamortized discounts of
 $80,747 and $380, respectively                    1,952,859        238,157
Warrant derivative liability                               -      1,685,108
Conversion option liability                                -        951,059
                                               -------------  -------------
  Total current liabilities                       14,477,413      9,266,379
                                               -------------  -------------
LONG TERM LIABILITIES
Related party convertible debt, net of debt
 discount of $0 and $165,611, respectively                 -        125,523
Convertible debt, net of debt discount of $0
 and $740,628, respectively                                -        529,742
Deferred revenue                                      61,592         87,527
                                               -------------  -------------
TOTAL LIABILITIES                                 14,539,005     10,009,171
                                               -------------  -------------

STOCKHOLDERS' DEFICIT
Series D Convertible Preferred Stock, $.01 par
 value; 850 shares authorized; 300 shares
 issued and outstanding on September 30, 2017
 and December 31, 2016, respectively
 (Liquidation value of $300,000)                           3              3
Series G Convertible Preferred Stock, $.01 par
 value; 240,000 shares authorized; 80,570
 shares issued and outstanding on September
 30, 2017 and December 31, 2016, respectively            806            866
Series H Convertible Preferred Stock, $.01 par
 value; 10,000 shares authorized; 10,000
 shares issued and outstanding on September
 30, 2017 and December 31, 2016, respectively            100            100
Series H2 Convertible Preferred Stock, $.01
 par value; 21 shares authorized; 21 shares
 issued and outstanding on September 30, 2017
 and December 31, 2016, respectively                       -              -
Series J Convertible Preferred Stock, $.01 par
 value; 6,250 shares authorized; 3,458 shares
 issued and outstanding on September 30, 2017
 and December 31, 2016, respectively                      34             35
Series K Convertible Preferred Stock, $.01 par
 value; 15,000 shares authorized; 6,816 shares
 issued and outstanding on September 30, 2017
 and December 31, 2016, respectively                      68             68
Common stock, $.01 par value; 100,000,000
 shares authorized; 1,154,422 and 1,033,328
 shares issued and outstanding on September
 30, 2017 and December 31, 2016, respectively         11,544         10,333
Warrants to acquire common stock                   9,721,627      6,325,102
Additional paid-in capital                        29,976,405     27,544,265
Accumulated other comprehensive income                 6,190              -
Accumulated deficit                              (52,367,211)   (42,264,190)
                                               -------------  -------------
  Total stockholders' deficit                    (12,650,434)    (8,383,418)
                                               -------------  -------------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT    $   1,888,571  $   1,625,753
                                               =============  =============

Investor Contacts:
Richard T. Schumacher
President & CEO
(508) 230-1828 (T)

Joseph L. Damasio
VP of Finance and CFO
(508) 230-1828 (T)

Jeffrey N. Peterson
Chairman of the Board
(650) 812-8121 (T)

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...